Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Adlai Nortye Ltd. Sponsored ADR ( (ANL) ).
On December 29, 2025, Adlai Nortye Ltd. announced an exclusive licensing agreement granting Jiangsu Aosaikang Pharmaceutical (ASK Pharm) rights to develop, manufacture and commercialize its pan-RAS (ON) inhibitor AN9025 in mainland China, Hong Kong and Macao, while retaining rights elsewhere. The deal could be worth up to RMB 1.6 billion (about USD 230 million) for Adlai Nortye, including more than USD 20 million in upfront and near-term milestone payments and tiered royalties on net sales, and is intended to accelerate the clinical and commercial development of AN9025 in RAS-mutated cancers, with a phase I trial expected to begin in the first quarter of 2026; the collaboration also strengthens Adlai Nortye’s RAS-focused oncology platform and provides ASK Pharm with a high-barrier, front-line innovation asset for its Chinese oncology portfolio.
More about Adlai Nortye Ltd. Sponsored ADR
Adlai Nortye Ltd. is a global clinical-stage biotechnology company focused on developing innovative cancer therapies. With dual R&D operations in the U.S. and China, it is building a pipeline around next-generation cancer immunotherapies—such as tri-functional fusion proteins and oral PD-L1 inhibitors—and RAS-targeting treatments, including the oral pan-RAS(ON) inhibitor AN9025 and a CEACAM5-targeting antibody-drug conjugate delivering a pan-RAS(ON) inhibitor directly to tumors.
Average Trading Volume: 18,021
Technical Sentiment Signal: Hold
Current Market Cap: $60.52M
For a thorough assessment of ANL stock, go to TipRanks’ Stock Analysis page.